Johnson VA - Search Results

1

Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine.

Johnson VA, Barlow MA, Chou TC, Fisher RA, Walker BD, Hirsch MS, Schooley RT. Johnson VA, et al. J Infect Dis. 1989 May;159(5):837-44. doi: 10.1093/infdis/159.5.837. J Infect Dis. 1989. PMID: 2785146

2

New developments in antiretroviral drug therapy for human immunodeficiency virus infections.

Johnson VA, Hirsch MS. Johnson VA, et al. AIDS Clin Rev. 1990:235-72. AIDS Clin Rev. 1990. PMID: 1707295 Review. No abstract available.

3

Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

Johnson VA, Merrill DP, Videler JA, Chou TC, Byington RE, Eron JJ, D'Aquila RT, Hirsch MS. Johnson VA, et al. J Infect Dis. 1991 Oct;164(4):646-55. doi: 10.1093/infdis/164.4.646. J Infect Dis. 1991. PMID: 1716649

4

New developments in combination chemotherapy of anti-human immunodeficiency virus drugs.

Johnson VA, Hirsch MS. Johnson VA, et al. Ann N Y Acad Sci. 1990;616:318-27. doi: 10.1111/j.1749-6632.1990.tb17852.x. Ann N Y Acad Sci. 1990. PMID: 2078026 Review. No abstract available.

5

Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A.

Johnson VA, Barlow MA, Merrill DP, Chou TC, Hirsch MS. Johnson VA, et al. J Infect Dis. 1990 Jun;161(6):1059-67. doi: 10.1093/infdis/161.6.1059. J Infect Dis. 1990. PMID: 2345291

6

Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3'-azido-3'-deoxythymidine.

Johnson VA, Walker BD, Barlow MA, Paradis TJ, Chou TC, Hirsch MS. Johnson VA, et al. Antimicrob Agents Chemother. 1989 Jan;33(1):53-7. doi: 10.1128/AAC.33.1.53. Antimicrob Agents Chemother. 1989. PMID: 2653214 Free PMC article.

7

HIV infection is blocked in vitro by recombinant soluble CD4.

Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, Tizard R, Walker BD, Hirsch MS, Schooley RT, et al. Fisher RA, et al. Among authors: johnson va. Nature. 1988 Jan 7;331(6151):76-8. doi: 10.1038/331076a0. Nature. 1988. PMID: 2829022

8

Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.

Eron JJ Jr, Johnson VA, Merrill DP, Chou TC, Hirsch MS. Eron JJ Jr, et al. Among authors: johnson va. Antimicrob Agents Chemother. 1992 Jul;36(7):1559-62. doi: 10.1128/AAC.36.7.1559. Antimicrob Agents Chemother. 1992. PMID: 1324648 Free PMC article.

9

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.

Johnson VA, Merrill DP, Chou TC, Hirsch MS. Johnson VA, et al. J Infect Dis. 1992 Nov;166(5):1143-6. doi: 10.1093/infdis/166.5.1143. J Infect Dis. 1992. PMID: 1328402

10

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Hirsch MS, et al. Among authors: johnson va. Clin Infect Dis. 2003 Jul 1;37(1):113-28. doi: 10.1086/375597. Epub 2003 Jun 23. Clin Infect Dis. 2003. PMID: 12830416

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters